Praxis Precision Medicines Inc
NASDAQ:PRAX
Praxis Precision Medicines Inc
Interest Income Expense
Praxis Precision Medicines Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Praxis Precision Medicines Inc
NASDAQ:PRAX
|
Interest Income Expense
$3.1m
|
CAGR 3-Years
181%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Praxis Precision Medicines Inc's Interest Income Expense?
Interest Income Expense
3.1m
USD
Based on the financial report for Dec 31, 2023, Praxis Precision Medicines Inc's Interest Income Expense amounts to 3.1m USD.
What is Praxis Precision Medicines Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
181%
Over the last year, the Interest Income Expense growth was 223%. The average annual Interest Income Expense growth rates for Praxis Precision Medicines Inc have been 181% over the past three years .